C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $547.9M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 12, 2026
- $363.7M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +25 vs. previous quarter
- 148
- 13F valueReported value at the end of Q2 2026
- $547.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $35.9M
- +1.0% year over year
- Net income, FY2025
- -$105.0M
- No comparable prior period
- Free cash flow, FY2025
- -$99.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $8.47M
- −24.6% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $105.0M (292.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 46.6M
- Shares sold short
- Change
- +3.86M
- +9.0% vs. previous
- Days to cover
- 15.14
- At average daily volume
Superinvestors holding CCCC, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CCCC at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by C4 Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 16, 2026 (view filing) | Jan 16 | Same day | Reyno LeonardChief Medical Officer | SSale | −10.0K | $2.22 | −$22.2K | −6.0%156.4K after | |
| Feb 18, 2025 (view filing) | Feb 14-18 | 4 days | Boyle Scott NChief Business Officer | SSale | −1.16K | $3.15 | −$3.65K | −1.1%107.8K after | 2 lots10b5-1 |
| Feb 10, 2023 (view filing) | Feb 8 | 2 days | Koppikar UtpalDirector | PPurchase | +5.67K | $5.60 | +$31.7K | New position5.67K after | |
| Apr 12, 2022 (view filing) | Apr 12 | Same day | Hirsch AndrewPresident & CEO | PPurchase | +10.0K | $8.40 | +$84.0K | New position10.0K after | |
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Crystal AdamChief Medical Officer | SSale | −15.0K | $31.67 | −$475.0K | −50.0%15.0K after | 2 lots |
| Dec 17, 2021 (view filing) | Dec 17 | Same day | Salter MalcolmDirector | SSale | −755 | $30.25 | −$22.8K | −6.4%11.0K after | |
| Nov 19, 2021 (view filing) | Nov 19 | Same day | Salter MalcolmDirector | SSale | −755 | $40.11 | −$30.3K | −6.1%11.7K after | |
| Oct 15, 2021 (view filing) | Oct 15 | Same day | Salter MalcolmDirector | SSale | −755 | $44.94 | −$33.9K | −5.7%12.5K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Crystal AdamChief Medical Officer | SSale | −15.0K | $45.43 | −$681.4K | −100.0%0 after | 3 lots |
| Sep 29, 2021 (view filing) | Sep 27 | 2 days | Prokupets ElenaDirector | SSale | −1.85K | $50.04 | −$92.6K | −0.4%503.1K after | 2 lots |
Top 10 13F holders, Q2 2026
See all 148 holdersThe largest institutional positions in C4 Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 8,867,338 | $41.4M | 0.00% | −205,062−2.3% | Reduced |
| Ra Capital Management, L.P. | 8,000,000 | $37.4M | 0.32% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,896,718 | $36.9M | 0.00% | +5,848,192+285.5% | Added |
| Lynx1 Capital Management LP | 7,326,691 | $34.2M | 3.95% | +327,789+4.7% | Added |
| Squadron Capital Management LLC | 7,200,000 | $33.6M | 11.51% | +4,950,000+220.0% | Added |
| Bain Capital Life Sciences Investors, LLC | 7,171,910 | $33.5M | 1.99% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 4,747,424 | $20.7M | 0.00% | +1,524,370+47.3% | Added |
| Vanguard Capital Management LLC | 4,417,731 | $20.6M | 0.00% | +555,879+14.4% | Added |
| Citadel Advisors LLC | 4,187,580 | $19.6M | 0.01% | +1,676,565+66.8% | Added |
| Goldman Sachs Group Inc | 3,530,991 | $16.5M | 0.00% | +1,143,613+47.9% | Added |
Holders of 5% or more of CCCC
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of C4 Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 13G/A | 9.99%15.4M shares | +2.69 ppfrom 7.30% | Nov 13, 20235 filings | Aug 14, 2026 | SEC |
| Soleus Capital Master Fund, L.P. | 13G/A | 9.99%10.4M shares | – | Apr 14, 20235 filings | Feb 12, 2026 | SEC |
| Sirenia Capital Management LP | 13G | 9.90%23.5M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Ra Capital Management, L.P. | 13G/A | 9.90%11.4M shares | 0.00 ppfrom 9.90% | Dec 26, 20234 filings | Aug 14, 2026 | SEC |
| Morgan Stanley | 13G/A | 8.00%8.86M shares | −1.30 ppfrom 9.30% | Feb 3, 20254 filings | Aug 12, 2026 | SEC |